Brexpiprazole is a novel D2 dopamine partial agonist.; IC50 Value: N/A; Target: Dopamine Receptor; in vitro: Brexpiprazole (OPC-34712) is a close structural analog of aripiprazole and shares some of its pharmacological properties. MedChem ExpressHY-15780

Brexpiprazole is a novel D2 dopamine partial agonist.;IC50 Value: N/A;Target: Dopamine Receptor;In vitro: Brexpiprazole (OPC-34712) is a close structural analog of aripiprazole and shares some of its pharmacological properties. Similarly to aripiprazole, brexpiprazole exhibits partial agonism of D2R and an enhanced affinity for specific serotonin receptors (e.g., 5-HT1A, 5-HT2A and 5-HT7). Currently [1].;In vivo: Brexpiprazole is in Phase III clinical trials for patients with schizophrenia and as adjunctive therapy for patients with major depressive disorder [1] MedChem ExpressHY-15780